In severe asthma, benralizumab reduced daily oral glucocorticoid dose and asthma exacerbations at 6 months

Research output: Contribution to journalComment/debatepeer-review

1 Scopus citations
Original languageEnglish (US)
Pages (from-to)JC43
JournalAnnals of internal medicine
Volume167
Issue number8
DOIs
StatePublished - Oct 17 2017

ASJC Scopus subject areas

  • Internal Medicine

Cite this